Radiation plus or minus BMX-001 for advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests two different ways of giving radiation before surgery for locally advanced rectal cancer, with or without an added study drug called BMX-001. It aims to see whether the shorter/longer radiation plans and BMX-001 improve cancer control and are safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma confirmed by pathology (lab test), and it’s stage II–III cancer that needs treatment before cure (total neoadjuvant therapy).
- You must be an adult (at least 19 years old for Nebraska).
- Your general health score (ECOG) must be 0 to 2.
- Your blood and organ tests must meet minimum levels (enough blood counts, liver tests not too high, and kidney function adequate).
- You must be able to do a recent imaging scan (CT chest/abdomen/pelvis or pelvic MRI) within 8 weeks before randomization.
- If you can become pregnant, you must have a negative pregnancy test and use two reliable birth-control methods during treatment and for 12 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a combination of short-course radiation, chemotherapy, and two types of immunotherapy (HLX07 and Serplulimab) before surgery for advanced rectal cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
This study tests a combination of a special diet supplement (beta-hydroxybutyrate), short radiation therapy, immunotherapy, and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improve treatment outcomes.
This study compares two different schedules of radiation (a short course versus a longer course) followed by standard chemotherapy and immunotherapy for advanced rectal cancer. It aims to see which approach works best to shrink the tumor before surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.